Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings ...

President Trump has said he plans to raise or impose new tariffs on a wide range of products, including pharmaceuticals. While Trump has openly discussed rolling out tariffs on China, Mexico and ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

US pharma major AbbVie has posted financial results for the fourth quarter and full year ended December 31, 2024, that pleased investors and sending the firm’s shares up 7.8% to $189.19 by mid-morning ...

UK pharma major AstraZeneca has scrapped its plans to invest £450 million in expanding ($559 million) to expand its vaccine plant in Speke, Liverpool, blaming a reduction in government support.

Organ Transplantation Immunosuppressive Drug Market. Global Organ Transplantation Immunosuppressive Drug market presents significant growth opportunities.

Sanford C. Bernstein upgraded shares of Sanofi (NASDAQ:SNY – Free Report) to a strong-buy rating in a report released on Thursday morning,Zacks.com reports. A number of other brokerages also recently ...

Sanofi (NASDAQ:SNY – Get Free Report) has been given a consensus recommendation of “Buy” by the three brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst ...

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...